Expression of Lewy body protein septin 4 in postmortem brain of Parkinson's disease and control subjects

Movement Disorders

Volumn 24, Issue 2, 2009, Pages 204-210

  Shehadeh, Lina ^a,b   Mitsi, Georgia ^c   Adi, Nikhil ^a   Bishopric, Nanette ^a   Papapetropoulos, Spyridon ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

Alpha synuclein; Amygdala; Gene expression; mRNA; Parkinson's disease; Postmorten brain; Protein; Septin 4; Substantia nigra

Indexed keywords

ALPHA SYNUCLEIN; SEPTIN; SEPTIN 4; UNCLASSIFIED DRUG;

AGED; AMYGDALOID NUCLEUS; ARTICLE; AUTOPSY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SUBSTANTIA NIGRA;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; AMYGDALA; CYTOSKELETAL PROTEINS; FEMALE; GENE EXPRESSION REGULATION; GTP PHOSPHOHYDROLASES; HUMANS; LEWY BODIES; MALE; NERVE TISSUE PROTEINS; PARKINSON DISEASE; POSTMORTEM CHANGES; RNA, MESSENGER; SUBSTANTIA NIGRA;

EID: 61649109808     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22306     Document Type: Article

References (30)

1. de Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:10-15.
2. Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 2006;7:306-318.
3. Papapetropoulos S, McCorquodale DS, Gonzalez J, Jean-Gilles L, Mash DC. Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations. Parkinsonism Relat Disord 2006;12:253-256.
4. Galvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: clinical and pathological implications. Arch Neurol 2001;58:186-190.
5. Ihara M, Tomimoto H, Kitayama H, et al. Association of the cytoskeletal GTP-binding protein Sept4/H5 with cytoplasmic inclusions found in Parkinson's disease and other synucleinopathies. J Biol Chem 2003;278:24095-24102.
6. Ihara M, Yamasaki N, Hagiwara A, et al. Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Neuron 2007;53:519-533.
7. Field CM, Kellogg D. Septins: cytoskeletal polymers or signalling GTPases? Trends Cell Biol 1999;9:387-394.
8. Fahn S, Elton RL, Members of the UPDRS development committee. Fann S, Marsden CD, Calne DB, Goldstein M, eds. Unified Parkinson's disease rating scale in Recent developments in Parkinson's disease. Macmillan Healthcare Information, 1987.
9. Papapetropoulos S, Maraganore DM, Adi N, Ffrench-Mullen J, McCorquodale D, Mash DC. Multiregional high-throughput gene expression profiling of Braak regions in Parkinson's disease. Mov Disord 2007;22:S136-S136.
10. Papapetropoulos S, Gonzalez J, Lieberman A, Villar JM, Mash DC. Dementia in Parkinson's disease: a post-mortem study in a population of brain donors. Int J Geriatr Psychiatry 2005;20:418-422.
11. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases (see comments). J Neurol Neurosurg Psychiatry 1992;55:181-184.
12. Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's Disease (CERAD). II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
13. Papapetropoulos S, Shehadeh L, McCorquodale D. Optimizing human post-mortem brain tissue gene expression profiling in Parkinson's disease and other neurodegenerative disorders: from target "fishing" to translational breakthroughs. J Neurosci Res 2007; 85:3013-3024.
14. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 1993;15:532-534, 536-537.
15. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
16. Harding AJ, Stimson E, Henderson JM, Halliday GM. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 2002;125:2431-2445.
17. Papapetropoulos S, Adi N, Mash DC, Shehadeh L, Bishopric N, Shehadeh L. Expression of alpha-synuclein mRNA in Parkinson's disease. Mov Disord 2007;22:1057-1059; author reply 1057.
18. Dachsel JC, Lincoln SJ, Gonzalez J, Ross OA, Dickson DW, Farrer MJ. The ups and downs of alpha-synuclein mRNA expression. Mov Disord 2007;22:293-295.
19. Moran LB, Croisier E, Duke DC, et al. Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra. Acta Neuropathol (Berl) 2007;113: 253-263.
20. Son JH, Kawamata H, Yoo MS, et al. Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons. J Neurochem 2005;94:1040-1053.
21. Choi P, Snyder H, Petrucelli L, et al. SEPT5_v2 is a parkin-binding protein. Brain Res Mol Brain Res 2003;117:179-189.
22. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci USA 2000;97:13354-13359.
23. Hashimoto M, Hsu LJ, Sisk A, et al. Human recombinant NACP/ alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res 1998;799:301-306.
24. Fujiwara H, Hasegawa M, Dohmae N, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002;4: 160-164.
25. Takahashi S, Inatome R, Yamamura H, Yanagi S. Isolation and expression of a novel mitochondrial septin that interacts with CRMP/CRAM in the developing neurones. Genes Cells 2003;8: 81-93.
26. Grunblatt E, Mandel S, Jacob-Hirsch J, et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 2004;111:1543-1573.
27. Lesnick TG, Papapetropoulos S, Mash DC, et al. A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet 2007;3:e98.
28. Schapira AH. Mitochondrial dysfunction in Parkinson's disease. Cell Death Differ 2007;14:1261-1266.
29. Lev N, Melamed E, Offen D. Apoptosis and Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:245-250.
30. Kinoshita A, Kinoshita M, Akiyama H, et al. Identification of septins in neurofibrillary tangles in Alzheimer's disease. Am J Pathol 1998;153:1551-1560.